Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (ATYR)
NASDAQ:ATYR
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -31.83%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and market opportunities, along with a solid financial position. However, there are challenges related to limited clinical studies for benchmarking and high unmet medical needs in the current market landscape.Company Guidance
During aTyr Pharma's fourth quarter and full year 2024 conference call, the company provided comprehensive guidance on their clinical developments and strategic outlook. They highlighted the completion of enrollment in the pivotal Phase 3 EFZO-FIT study for efzofitimod, aimed at treating pulmonary sarcoidosis. This trial involves 268 patients across 85 centers in nine countries, testing doses of 3 mg/kg and 5 mg/kg against a placebo over 52 weeks, with a primary endpoint focused on steroid reduction. The company also noted that 75% of diagnosed sarcoidosis patients are prescribed steroids, with the U.S. patient population being 30% larger than previously estimated. Additionally, they have observed four positive data and safety monitoring board reviews with no safety concerns. Financially, aTyr ended 2024 with $75.1 million in cash, supplemented by $18.8 million from an ATM offering. They project their cash runway will last through a year following the Phase 3 readout. The company also discussed plans for commercial readiness and the potential for efzofitimod in a $2-5 billion ILD market, with sarcoidosis representing a significant portion.Completion of Enrollment in EFZO-FIT Phase 3 Study
aTyr completed enrollment in the global pivotal Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis, enrolling 268 patients across 85 centers in 9 countries.
Positive Safety Profile in Phase 3 Study
Four positive data and safety monitoring board reviews for EFZO-FIT identified no safety concerns, recommending the study to continue unmodified.
Increased Market Opportunity for Efzofitimod
Recent analysis shows the U.S. patient population for sarcoidosis is 30% higher than previously estimated, suggesting a larger market opportunity for efzofitimod.
Publication in Science Translational Medicine
An extensive manuscript on efzofitimod's mechanism of action and preclinical data was published in the journal Science Translational Medicine, validating its immunomodulatory properties.
Strong Financial Position and Cash Runway
aTyr ended 2024 with $75.1 million in cash and raised an additional $18.8 million, with a cash runway expected to fund operations through one year following the Phase 3 EFZO-FIT readout.
---
ATYR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ATYR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $3.99 | $3.97 | -0.50% |
| Nov 07, 2024 | $3.10 | $3.12 | +0.65% |
| Aug 13, 2024 | $1.74 | $1.85 | +6.32% |
| May 02, 2024 | $1.60 | $1.61 | +0.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does aTyr Pharma (ATYR) report earnings?
aTyr Pharma (ATYR) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is aTyr Pharma (ATYR) earnings time?
aTyr Pharma (ATYR) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ATYR EPS forecast?
ATYR EPS forecast for the fiscal quarter 2025 (Q1) is -0.19.
---